文獻摘要: Cost utility analysis of 177Lu PSMA 617 radioligand therapy in second line and third line treatment for metastatic castration resistant prostate cancer mCRPC in Germany

Objectives 評估了 177Lu-PSMA-617 radioligand therapy (PRLT) 用於德國 metastatic castration-resistant prostate cancer (mCRPC) 的成本效益，從法定健康保險的角度。 Model I (三線治療：PRLT + Standard-of-Care (SoC) 對比單獨 SoC) 顯示 PRLT + SoC 增加了成本 (€27,200) 並增加了 Quality-Adjusted Life Ye...